ReviewWorld journal of gastroenterology2014
Attempts to enhance the eradication rate of Helicobacter pylori infection.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Effectiveness of Classic Triple Therapy Compared with Alternative Regimens for EradicatingMedicina (Kaunas, Lithuania) · 2025Pooled it
- Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions.Gastroenterology · 2018Pooled it
- Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment.PloS one · 2018Pooled it
- Lactiplantibacillus plantarum DS1073 protects the gastric mucosa under Helicobacter pylori infection and ethanol stress.Cell communication and signaling : CCS · 2026Article
- Article
- [Study on the Inhibitory Effect and Mechanism of Trans-2-Decenal onSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Article
- Computer-aided diagnosis in real-time endoscopy for all stages of gastric carcinogenesis: Development and validation study.United European gastroenterology journal · 2024Article
- Detection of Clarithromycin Resistance in Helicobacter pylori Using MmaxSure™ H. pylori & ClaR Assay.Digestive diseases (Basel, Switzerland) · 2024Article
- Clinical Decision Support System for All Stages of Gastric Carcinogenesis in Real-Time Endoscopy: Model Establishment and Validation Study.Journal of medical Internet research · 2023Article
- Quantitative multiplex real-time polymerase chain reaction assay for the detection of Helicobacter pylori and clarithromycin resistance.BMC microbiology · 2023Article
- The Anti-Helicobacter pylori effects of Limosilactobacillus reuteri strain 2892 isolated from Camel milk in C57BL/6 mice.World journal of microbiology & biotechnology · 2023Article
- Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin forAntibiotics (Basel, Switzerland) · 2021Article
- Telephone-Based Reeducation of Drug Administration forGastroenterology research and practice · 2020Article
- Simvastatin improves the eradication rate ofInfection and drug resistance · 2019Article
- Key lime (Gut pathogens · 2018Article
- Review article: the global emergence of Helicobacter pylori antibiotic resistance.Alimentary pharmacology & therapeutics · 2016Review
- Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions.World journal of gastroenterology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing rates of antimicrobial resistance to clarithromycin and metronidazole present challenges in maintaining optimal eradication rates. Knowledge of local antibiotic resistance and consumption pattern is important in selecting a reliable regimen. In addition, adverse effect profiles of therapeutic regimens are important and must be addressed to enhance compliance rates. Various methods of enhancing the eradication rates of Helicobacter pylori (H. pylori) have been investigated, including changing combinations or durations of established drugs, adding adjuvant drugs, or development of new molecules or agents. Bismuth-containing quadruple, sequential, concomitant, and levofloxacin-based triple therapies are replacing the long-standing standard of the triple regimen. Despite the encouraging results of these regimens, individualized approaches like treatment after antibiotics resistance test or CYP2C19 genotyping would be the mainstream of future therapy. Because scientific, economic, and technical problems make these advance therapies unfit for widespread use, future development for H. pylori therapy should be directed to overcome individualized antibiotic resistance. Although various novel regimens and additive agents have indicated favorable outcomes, more studies or validations are needed to become a mainstream H. pylori therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.